TY - JOUR
T1 - Can Machine Learning Models Predict Asparaginase-associated Pancreatitis in Childhood Acute Lymphoblastic Leukemia
AU - Nielsen, Rikke L.
AU - Wolthers, Benjamin O.
AU - Helenius, Marianne
AU - Albertsen, Birgitte K.
AU - Clemmensen, Line
AU - Nielsen, Kasper
AU - Kanerva, Jukka
AU - Niinimäki, Riitta
AU - Frandsen, Thomas L.
AU - Attarbaschi, Andishe
AU - Barzilai, Shlomit
AU - Colombini, Antonella
AU - Escherich, Gabriele
AU - Aytan-Aktug, Derya
AU - Liu, Hsi Che
AU - Möricke, Anja
AU - Samarasinghe, Sujith
AU - Van Der Sluis, Inge M.
AU - Stanulla, Martin
AU - Tulstrup, Morten
AU - Yadav, Rachita
AU - Zapotocka, Ester
AU - Schmiegelow, Kjeld
AU - Gupta, Ramneek
N1 - Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
PY - 2022/4/1
Y1 - 2022/4/1
N2 - Asparaginase-associated pancreatitis AAP frequently affects children treated for acute lymphoblastic leukemia ALL causing severe acute and persisting complications. Known risk factors such as asparaginase dosing, older age and single nucleotide polymorphisms SNPs have insufficient odds ratios to allow personalized asparaginase therapy. In this study, we explored machine learning strategies for prediction of individual AAP risk. We integrated information on age, sex, and SNPs based on Illumina Omni2.5exome-8 arrays of patients with childhood ALL N=1564, 244 with AAP 1.0 to 17.9 yo from 10 international ALL consortia into machine learning models including regression, random forest, AdaBoost and artificial neural networks. A model with only age and sex had area under the receiver operating characteristic curve ROC-AUC of 0.62. Inclusion of 6 pancreatitis candidate gene SNPs or 4 validated pancreatitis SNPs boosted ROC-AUC somewhat 0.67 while 30 SNPs, identified through our AAP genome-wide association study cohort, boosted performance 0.80. Most predictive features included rs10273639 PRSS1-PRSS2, rs10436957 CTRC, rs13228878 PRSS1/PRSS2, rs1505495 GALNTL6, rs4655107 EPHB2 and age 1 to 7 y. Second AAP following asparaginase re-exposure was predicted with ROC-AUC: 0.65. The machine learning models assist individual-level risk assessment of AAP for future prevention trials, and may legitimize asparaginase re-exposure when AAP risk is predicted to be low.
AB - Asparaginase-associated pancreatitis AAP frequently affects children treated for acute lymphoblastic leukemia ALL causing severe acute and persisting complications. Known risk factors such as asparaginase dosing, older age and single nucleotide polymorphisms SNPs have insufficient odds ratios to allow personalized asparaginase therapy. In this study, we explored machine learning strategies for prediction of individual AAP risk. We integrated information on age, sex, and SNPs based on Illumina Omni2.5exome-8 arrays of patients with childhood ALL N=1564, 244 with AAP 1.0 to 17.9 yo from 10 international ALL consortia into machine learning models including regression, random forest, AdaBoost and artificial neural networks. A model with only age and sex had area under the receiver operating characteristic curve ROC-AUC of 0.62. Inclusion of 6 pancreatitis candidate gene SNPs or 4 validated pancreatitis SNPs boosted ROC-AUC somewhat 0.67 while 30 SNPs, identified through our AAP genome-wide association study cohort, boosted performance 0.80. Most predictive features included rs10273639 PRSS1-PRSS2, rs10436957 CTRC, rs13228878 PRSS1/PRSS2, rs1505495 GALNTL6, rs4655107 EPHB2 and age 1 to 7 y. Second AAP following asparaginase re-exposure was predicted with ROC-AUC: 0.65. The machine learning models assist individual-level risk assessment of AAP for future prevention trials, and may legitimize asparaginase re-exposure when AAP risk is predicted to be low.
KW - acute lymphoblastic leukemia
KW - artificial intelligence
KW - pediatric hematology/oncology
KW - translational research
KW - treatment toxicity
KW - Genome-Wide Association Study
KW - Humans
KW - Pancreatitis/chemically induced
KW - Machine Learning
KW - Antineoplastic Agents/adverse effects
KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy
KW - Child
KW - Asparaginase/adverse effects
UR - http://www.scopus.com/inward/record.url?scp=85117820186&partnerID=8YFLogxK
U2 - 10.1097/MPH.0000000000002292
DO - 10.1097/MPH.0000000000002292
M3 - Article
C2 - 35226426
AN - SCOPUS:85117820186
SN - 1077-4114
VL - 44
SP - E628-E636
JO - Journal of Pediatric Hematology/Oncology
JF - Journal of Pediatric Hematology/Oncology
IS - 3
ER -